CancerDrs Find care

Multiple Myeloma clinical trials in Colorado

38 actively recruiting multiple myeloma trials at 23 sites across Colorado.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in diff…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT03937635
Sites in Colorado:
  • Rocky Mountain Cancer Centers-Aurora — Aurora, Colorado
  • The Medical Center of Aurora — Aurora, Colorado
  • Boulder Community Hospital — Boulder, Colorado
  • Rocky Mountain Cancer Centers-Boulder — Boulder, Colorado
  • Rocky Mountain Cancer Centers - Centennial — Centennial, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in Colorado:
  • Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
  • Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
  • Saint Francis Cancer Center — Colorado Springs, Colorado
  • Porter Adventist Hospital — Denver, Colorado
  • Mercy Medical Center — Durango, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are consid…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05561387
Sites in Colorado:
  • Rocky Mountain Regional VA Medical Center — Aurora, Colorado
  • Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
  • Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
  • Saint Francis Cancer Center — Colorado Springs, Colorado
  • Porter Adventist Hospital — Denver, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years …

Sponsor: Pfizer
NCT ID: NCT06152575
Sites in Colorado:
  • UCHealth Poudre Valley Hospital — Fort Collins, Colorado
  • UCHealth Harmony — Fort Collins, Colorado
  • UCHealth Greeley Hospital — Greeley, Colorado
  • UCHealth Longs Peak Hospital — Longmont, Colorado
  • UCHealth Longs Peak Medical Center — Longmont, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple m…

Sponsor: Celgene
NCT ID: NCT05519085
Sites in Colorado:
  • Local Institution - 0381 — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, inclu…

Sponsor: Kite, A Gilead Company
NCT ID: NCT06413498
Sites in Colorado:
  • Colorado Blood Cancer Institute — Denver, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney fail…

Sponsor: AbbVie
NCT ID: NCT06158841
Sites in Colorado:
  • Rocky Mountain Cancer Centers - Lone Tree /ID# 278320 — Lone Tree, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).

Sponsor: Bristol-Myers Squibb
NCT ID: NCT05827016
Sites in Colorado:
  • Rocky Mountain Cancer Centers — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, …

Sponsor: AstraZeneca
NCT ID: NCT07391657
Sites in Colorado:
  • Research Site — Denver, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as …

Sponsor: European Myeloma Network B.V.
NCT ID: NCT05243797
Sites in Colorado:
  • University of Colorado Hospital — Aurora, Colorado
  • Colorado Blood Cancer Institute — Denver, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dex…

Sponsor: Pfizer
NCT ID: NCT05020236
Sites in Colorado:
  • UCHealth Poudre Valley Hospital — Fort Collins, Colorado
  • UCHealth Harmony — Fort Collins, Colorado
  • UCHealth Greeley Hospital — Greeley, Colorado
  • UCHealth - Medical Center of the Rockies — Loveland, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.

Sponsor: GlaxoSmithKline
NCT ID: NCT06679101
Sites in Colorado:
  • GSK Investigational Site — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney fail…

Sponsor: AbbVie
NCT ID: NCT07095452
Sites in Colorado:
  • Colorado Blood Cancer Institute /ID# 279080 — Denver, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06297226
Sites in Colorado:
  • Colorado Blood Cancer Institute — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Selinexor and Backbone Treatments of Multiple Myeloma Patients

This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and ne…

Sponsor: Karyopharm Therapeutics Inc
NCT ID: NCT02343042
Sites in Colorado:
  • Sarah Cannon-Colorado Blood Cancer Institute — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem c…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT05828511
Sites in Colorado:
  • Colorado Blood Cancer Institute/SCRI — Denver, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of…

Sponsor: University of Alabama at Birmingham
NCT ID: NCT05231629
Sites in Colorado:
  • Colorado Blood Cancer Institute — Denver, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy. The primary objective of this study is to compare the…

Sponsor: SCRI Development Innovations, LLC
NCT ID: NCT06974786
Sites in Colorado:
  • Colorado Blood Cancer Institute — Denver, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better charac…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06500884
Sites in Colorado:
  • Colorado Blood Cancer Institute — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney fail…

Sponsor: AbbVie
NCT ID: NCT06892522
Sites in Colorado:
  • Colorado Blood Cancer Institute /ID# 273129 — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need to be treated again. The study consists…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06292780
Sites in Colorado:
  • Colorado Blood Cancer Institute/SCRI — Denver, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM…

Sponsor: Irene Ghobrial, MD
NCT ID: NCT05469893
Sites in Colorado:
  • Colorado Blood Cancer Institute — Denver, Colorado
View on ClinicalTrials.gov →

Showing 25 of 38 trials with sites in Colorado. See all multiple myeloma trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20